Physician profile
Rohit R Amin
NPI 1316139041
$560,307.89
in general payments reported to CMS, 2019-2025
60 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $81K · 2021: $105K · 2022: $95K · 2023: $53K · 2024: $34K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $26K · Travel and Lodging: $19K · Consulting Fee: $6,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,750 · Entertainment: $144 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,716.50 |
| Food and Beverage | $25,655.43 |
| Travel and Lodging | $18,787.38 |
| Consulting Fee | $6,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,750.00 |
| Entertainment | $144.12 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $246,206.87 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $171,160.14 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Inari Medical, INC. | $66,729.45 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $23,341.28 | 2019-2025 | Mitraclip, Amplatzer Talisman, Triclip |
| Stryker Corporation | $7,085.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Limflow System |
| Bayer Healthcare Pharmaceuticals INC. | $7,066.82 | 2019-2022 | |
| Abiomed | $6,260.12 | 2019-2025 | Impella |
| Penumbra, INC. | $5,595.31 | 2020-2025 | Indigo System, Penumbra System |
| Ancora Heart, INC. | $5,405.59 | 2023-2025 | Accucinch |
| Shockwave Medical, INC | $3,616.40 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Novartis Pharmaceuticals Corporation | $2,672.03 | 2019-2025 | |
| Medtronic, INC. | $1,564.12 | 2021-2025 | Venaseal, Corevalve Evolut R, Symplicity G3 |
| Boston Scientific Corporation | $1,396.24 | 2020-2025 | Watchman, Watchman Flx, Eluvia |
| Recor Medical INC | $1,198.50 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| United Therapeutics Corporation | $1,130.13 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,120.85 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $914.34 | 2019-2025 | Opsumit, Uptravi |
| Endotronix, INC. | $891.59 | 2021-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.74 | 2019-2025 | Jardiance |
| Imperative Care, INC | $473.06 | 2023-2024 | Symphony Catheter, Prodigy Catheter |
| Pfizer INC. | $459.24 | 2019-2025 | |
| Philips North America LLC | $456.80 | 2019-2025 | (Bz1) Tack Endovascular Systems Btk, Igt Devices Undivided, (Br5) Peripheral Ivus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $416.34 | 2019-2025 | Lifevest |
| Opsens INC. | $389.60 | 2022-2023 | Optowire |
| Medtronic Vascular, INC. | $330.81 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $310.05 | 2019-2024 | Camzyos |
| Procyrion, INC. | $298.86 | 2024 | |
| Edwards Lifesciences Corporation | $294.22 | 2019-2025 | Evoque |
| Merck Sharp & Dohme LLC | $272.95 | 2024-2025 | Winrevair, Verquvo |
| Angiodynamics, INC. | $249.57 | 2024-2025 | Angiovac |
| Sanofi-Aventis U.S. LLC | $240.76 | 2019-2021 | |
| Livanova USA, INC. | $207.93 | 2023 | Tandemlife |
| Cook Medical LLC | $175.99 | 2019-2023 | Zilver Ptx |
| W. L. Gore & Associates, INC. | $169.30 | 2019-2023 | Gore Septal Occluder |
| Terumo Medical Corporation | $168.03 | 2020-2025 | Heartrail, Glidewire, Tr Band |
| Scpharmaceuticals INC. | $158.49 | 2023-2024 | |
| Bard Peripheral Vascular, INC. | $151.99 | 2025 | Venclose Maven Catheter |
| Teleflex LLC | $131.44 | 2025 | Guideliner |
| Heartflow, INC. | $116.75 | 2022 | |
| Janssen Scientific Affairs, LLC | $113.84 | 2022 | |
| Contego Medical, INC | $95.20 | 2024 | |
| Chiesi USA, INC. | $84.54 | 2022 | |
| Cardiva Medical, INC. | $81.82 | 2022 | |
| Cardiovascular Systems INC. | $81.66 | 2019 | |
| Sensible Medical Innovations INC | $79.64 | 2019 | |
| Biotronik INC. | $77.92 | 2025 | Orsiro Mission |
| Becton, Dickinson and Company | $69.02 | 2024 | Venclose Maven Catheter |
| Esperion Therapeutics, INC. | $50.83 | 2025 | Nexletol |
| Gilead Sciences, INC. | $48.72 | 2019 | |
| Novo Nordisk INC | $48.07 | 2019-2023 | Rybelsus, Ozempic |
| Ge Healthcare | $38.75 | 2019-2024 | |
| Irhythm Technologies, INC. | $15.64 | 2024 | Zio Xt Patch |
| Amarin Pharma, INC. | $13.34 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.08 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$137,659.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.